Overall, these in vivo experiments suggest MET amplified tumors and select MET polysomy osimertinib-resistant EGFR-mutant NSCLC tumors can benefit from combination therapy with osimertinib and savolitinib. This evidence concerns the gene MET and non-small cell lung carcinoma.